Assembly Biosciences Price to Free Cash Flow Ratio 2010-2024 | ASMB
Historical price to free cash flow ratio values for Assembly Biosciences (ASMB) since 2010.
For more information on how our historical price data is adjusted see the Stock Price Adjustment Guide.
| Assembly Biosciences Price to Free Cash Flow Ratio Historical Data |
| Date |
Stock Price |
TTM FCF per Share |
Price to FCF Ratio |
| 2024-11-01 |
16.89 |
|
2.36 |
| 2024-06-30 |
13.72 |
$7.15 |
1.92 |
| 2024-03-31 |
13.30 |
$7.08 |
1.88 |
| 2023-12-31 |
9.84 |
$4.92 |
2.00 |
| 2023-09-30 |
10.62 |
$-16.45 |
0.00 |
| 2023-06-30 |
13.80 |
$-18.20 |
0.00 |
| 2023-03-31 |
10.08 |
$-19.61 |
0.00 |
| 2022-12-31 |
15.60 |
$-20.96 |
0.00 |
| 2022-09-30 |
19.68 |
$-22.62 |
0.00 |
| 2022-06-30 |
25.20 |
$-21.75 |
0.00 |
| 2022-03-31 |
24.72 |
$-22.63 |
0.00 |
| 2021-12-31 |
27.96 |
$-26.53 |
0.00 |
| 2021-09-30 |
41.76 |
$-28.68 |
0.00 |
| 2021-06-30 |
46.56 |
$-21.85 |
0.00 |
| 2021-03-31 |
55.20 |
$-23.60 |
0.00 |
| 2020-12-31 |
72.60 |
$-21.49 |
0.00 |
| 2020-09-30 |
197.28 |
$-21.90 |
0.00 |
| 2020-06-30 |
279.84 |
$-33.18 |
0.00 |
| 2020-03-31 |
177.96 |
$-35.90 |
0.00 |
| 2019-12-31 |
245.52 |
$-39.14 |
0.00 |
| 2019-09-30 |
117.96 |
$-41.19 |
0.00 |
| 2019-06-30 |
161.88 |
$-37.57 |
0.00 |
| 2019-03-31 |
236.28 |
$-37.05 |
0.00 |
| 2018-12-31 |
271.44 |
$-34.38 |
0.00 |
| 2018-09-30 |
445.68 |
$-30.35 |
0.00 |
| 2018-06-30 |
470.52 |
$-33.45 |
0.00 |
| 2018-03-31 |
589.68 |
$-32.84 |
0.00 |
| 2017-12-31 |
543.00 |
$0.67 |
806.95 |
| 2017-09-30 |
419.04 |
$-0.08 |
0.00 |
| 2017-06-30 |
247.80 |
$2.36 |
104.99 |
| 2017-03-31 |
305.88 |
$6.30 |
48.53 |
| 2016-12-31 |
145.80 |
$-24.41 |
0.00 |
| 2016-09-30 |
86.52 |
$-21.71 |
0.00 |
| 2016-06-30 |
66.60 |
$-19.79 |
0.00 |
| 2016-03-31 |
60.24 |
$-16.78 |
0.00 |
| 2015-12-31 |
90.12 |
$-14.34 |
0.00 |
| 2015-09-30 |
114.72 |
$-18.68 |
0.00 |
| 2015-06-30 |
231.12 |
$-12.46 |
0.00 |
| 2015-03-31 |
158.88 |
$-15.83 |
0.00 |
| 2014-12-31 |
94.32 |
$-25.94 |
0.00 |
| 2014-09-30 |
98.28 |
$-34.19 |
0.00 |
| 2014-06-30 |
78.60 |
$-50.66 |
0.00 |
| 2014-03-31 |
76.50 |
$-53.81 |
0.00 |
| 2013-12-31 |
229.20 |
$-55.10 |
0.00 |
| 2013-09-30 |
173.40 |
$-53.30 |
0.00 |
| 2013-06-30 |
144.00 |
$-62.52 |
0.00 |
| 2013-03-31 |
179.40 |
$-86.77 |
0.00 |
| 2012-12-31 |
129.60 |
$-100.85 |
0.00 |
| 2012-09-30 |
214.80 |
$-202.44 |
0.00 |
| 2012-06-30 |
256.20 |
$-203.18 |
0.00 |
| 2012-03-31 |
598.20 |
$-186.05 |
0.00 |
| 2011-12-31 |
480.48 |
$-615.86 |
0.00 |
| 2011-06-30 |
885.60 |
$-543.61 |
0.00 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Generic Drugs |
$0.107B |
$0.007B |
|
Assembly Biosciences, Inc. is a biopharmaceutical company. It develops therapies for infectious diseases and other disorders of the gastrointestinal (GI) system. Assembly's product portfolio consists of two late stage assets: VEN 307 for relief from pain associated with anal fissures and VEN 308 for the treatment of fecal incontinence. The Company is also developing novel microbiome-based technology for targeted oral delivery of therapeutic bacteria, complex proteins, viral antigens and small molecules to treat intractable infectious diseases of the GI tract, such as C. difficile infections. Assembly Biosciences Inc., formerly known as Ventrus Biosciences, Inc., is based in New York.
|
